Couple: Diacetyl In Microwave Popcorn Caused Permanent Lung Disease
ST. LOUIS - A couple whose lawsuit against popcorn manufacturers was dismissed by an Iowa federal court filed a brief in the Eighth Circuit U.S. Court of Appeals on Feb. 6 contending that their claims for personal injury related to alleged exposure to diacetyl and pentanedione, the chemicals used to make artificial butter flavoring in popcorn, are valid because "it has been proven" that diacetyl can cause the permanent lung disease known as bronchiolitis obliterans (David Stults, et al. v. American Popcorn Company, No. 14-3658, 8th Cir.).
Long-term survival after lung transplantation (LTx) is hampered by chronic lung allograft dysfunction, with bronchiolitis obliterans syndrome (BOS) as its most common phenotype. Bronchiectasis (BRECT), hyperinflation and airtrapping are considered the key features of BOS on chest CT. We investigated whether chest CT and key features have prognostic value at BOS diagnosis in patients with established BOS after LTx.
Chronic Allograft Dysfunction (CLAD) with Bronchiolitis obliterans (BOS) phenotype is a major limitation for long term survival after lung transplantation (LT). Predictive biomarkers for BOS are unavailable. Purpose of our study was to establish a tractable system to evaluate the effects of pre-transplant antibodies to self-antigens (AutoAbs) and to examine specific patterns that correlate with BOS.
Chronic Lung Allograft Dysfunction (CLAD) is characterized by airway epithelial damage and fibrosis. The origin and initiation of fibrosis are poorly understood. We hypothesized that immune mediators in bronchoalveolar lavage (BAL) predict bronchiolitis obliterans syndrome (BOS), a form of CLAD, and poor survival. In a multi-center observational study, we investigated the role of proinflammatory cytokines as biomarkers for poor outcome after lung transplant (LTx).
Bronchiolitis obliterans syndrome (BOS) and restrictive allograft syndrome (RAS), have been identified as main phenotypes of chronic lung allograft dysfunction (CLAD), however patients can change phenotype. We aimed to describe incidence, prognosis, radiology, pulmonary function and pathology in this mixed group of CLAD.
Restrictive chronic lung allograft dysfunction (rCLAD) is associated with decreased survival but individual prognosis remains variable. Increased numbers of colony-forming units (CFU) of mesenchymal stromal cells (MSC) —the effector cells in fibroproliferation—derived from bronchoalveolar lavage (BAL) fluid have been associated with developing bronchiolitis obliterans syndrome (BOS). However, the prognostic significance of MSC in rCLAD is unknown.
Despite the growing experience in lung transplantation a significant number of patients rapidly succumb to chronic rejection in the form of bronchiolitis obliterans (OB). The reasons for such discrepancies are unknown but have been suspected to relate to individual variability in gut and lung microbiome.
The objective of the present retrospective investigation was to evaluate hospital-related costs and the clinical value of ECP when applied as an adjunct to the local standard therapy of BOS compared to standard treatment alone.
The major obstacle for long-term survival after successful lung transplantation is the development of chronic lung allograft dysfunction (CLAD). It has been shown that nintedanib, an intracellular inhibitor of receptor tyrosine kinases, has a beneficial effect in the treatment of neoplastic diseases and idiopathic pulmonary fibrosis. Nintedanib influences three major angiogenic signalling pathways by blocking the receptors for: platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF).
The use of gold nanoparticles (GNPs) as local targeted drug delivery system are a promising issue for several orphan diseases. Bronchiolitis obliterans syndrome (BOS) represents about 70% of cases of chronic lung allograft dysfunction limiting long term survival after lung transplant, and occurs also as chronic pulmonary involvement in the context of GVHD. To now treatment strategies in BOS are scarce and poorly effective. In the present work, we investigated the effect of GNP decorated with the half chain of monoclonal antibody against CD44 (GNP-HC), surface receptor overexpressed by primary BOS derived mesenchymal cells ...
In this study we aimed to characterize miR-21 expression and other markers of EMT in lung tissue of BOS and RAS patients.